Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 17.44M P/E - EPS this Y - Ern Qtrly Grth -
Income -4.29M Forward P/E -29.43 EPS next Y - 50D Avg Chg 10.00%
Sales 36.75k PEG - EPS past 5Y - 200D Avg Chg 20.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -26.00%
Recommedations - Quick Ratio 0.02 Shares Outstanding 10.89M 52W Low Chg 845.00%
Insider Own 50.42% ROA -417.17% Shares Float 5.54M Beta 0.61
Inst Own - ROE - Shares Shorted/Prior -/- Price 2.06
Gross Margin 49.38% Profit Margin - Avg. Volume 633 Target Price -
Oper. Margin -33,852.95% Earnings Date Aug 13 Volume 5 Change 0.00%
About BIOCORRX INC

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program for substance abuse that includes peer recovery support; and distributes UnCraveRx weight loss management program, a medically assisted weight management program. The company is also developing BICX101, an injectable and implantable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Lucido Louis C. Director Director Jan 24 Buy 1.20 200 240 101,259 01/25/23
Lucido Louis C. Director Director Jan 13 Buy 1.13 4,000 4,520 101,059 01/17/23
Lucido Louis C. Director Director Dec 12 Buy 0.84 5,000 4,200 89,425 12/15/22
Lucido Louis C. Director Director Aug 29 Buy 2.11 3,878 8,183 80,385 08/31/22
Lucido Louis C. Director Director Aug 25 Buy 2.15 1,060 2,279 76,507 08/29/22